High expression of oleoyl-ACP hydrolase underpins life-threatening respiratory viral diseases
- PMID: 39137778
- DOI: 10.1016/j.cell.2024.07.026
High expression of oleoyl-ACP hydrolase underpins life-threatening respiratory viral diseases
Abstract
Respiratory infections cause significant morbidity and mortality, yet it is unclear why some individuals succumb to severe disease. In patients hospitalized with avian A(H7N9) influenza, we investigated early drivers underpinning fatal disease. Transcriptomics strongly linked oleoyl-acyl-carrier-protein (ACP) hydrolase (OLAH), an enzyme mediating fatty acid production, with fatal A(H7N9) early after hospital admission, persisting until death. Recovered patients had low OLAH expression throughout hospitalization. High OLAH levels were also detected in patients hospitalized with life-threatening seasonal influenza, COVID-19, respiratory syncytial virus (RSV), and multisystem inflammatory syndrome in children (MIS-C) but not during mild disease. In olah-/- mice, lethal influenza infection led to survival and mild disease as well as reduced lung viral loads, tissue damage, infection-driven pulmonary cell infiltration, and inflammation. This was underpinned by differential lipid droplet dynamics as well as reduced viral replication and virus-induced inflammation in macrophages. Supplementation of oleic acid, the main product of OLAH, increased influenza replication in macrophages and their inflammatory potential. Our findings define how the expression of OLAH drives life-threatening viral disease.
Keywords: MIS-C; OLAH; SARS-CoV-2 and RSV; fatal avian A/H7N9 influenza disease; influenza mouse model; life-threatening seasonal influenza; olah(−/−) mice; olah-driven macrophage-mediated disease severity; oleoyl-ACP hydrolase as key early driver of disease severity.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests H.A.M. and B.Y.C. consult for Ena Respiratory. A.G.R. received research support from Illumina. P.G.T. is on the SAB of Immunoscape and Cytoagents, consulted for JNJ, received travel support/honoraria from Illumina and 10× Genomics, and has patents related to TCR discovery. J.C.C. and P.G.T. have patents related to treating or reducing severity of viral infections, including SARS-CoV-2.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous